Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Dexcom (DXCM) over the last 16 years, with Q4 2025 value amounting to $6.9 million.

  • Dexcom's Other Working Capital Changes rose 18625.0% to $6.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.8 million, marking a year-over-year increase of 15517.24%. This contributed to the annual value of $14.8 million for FY2025, which is 15517.24% up from last year.
  • According to the latest figures from Q4 2025, Dexcom's Other Working Capital Changes is $6.9 million, which was up 18625.0% from $2.4 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Other Working Capital Changes registered a high of $97.9 million during Q1 2022, and its lowest value of -$31.6 million during Q3 2024.
  • In the last 5 years, Dexcom's Other Working Capital Changes had a median value of $550000.0 in 2022 and averaged $7.7 million.
  • Per our database at Business Quant, Dexcom's Other Working Capital Changes skyrocketed by 152580.65% in 2022 and then plummeted by 117692.31% in 2023.
  • Dexcom's Other Working Capital Changes (Quarter) stood at $3.1 million in 2021, then surged by 1525.81% to $50.4 million in 2022, then crashed by 112.1% to -$6.1 million in 2023, then tumbled by 31.15% to -$8.0 million in 2024, then soared by 186.25% to $6.9 million in 2025.
  • Its Other Working Capital Changes was $6.9 million in Q4 2025, compared to $2.4 million in Q3 2025 and $22.0 million in Q2 2025.